Skip to main content
OpenTrials
Completed

NCT Number: NCT07413133

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteer

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

CenExel ACT- Anaheim Clinical Trials /ID# 280481, Anaheim, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Body weight >= 35 kg.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).

Exclusion criteria

  • Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements, on a regular basis.
  • Participant uses any medications, vitamins and/or herbal supplements within the 14-day period prior to study treatment administration.
  • Participant has received any treatment by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study treatment administration.
  • Participant has prior exposure to a Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) agent.

Treatment and study plan

ABBV-8736

Drug

Intravenous Injection

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Up to At Least 3 Months

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

  2. Maximum Observed Serum Concentration (Cmax) of ABBV-8736

    Time frame: Up to At Least 3 Months

    Cmax of ABBV-8736.

  3. Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736

    Time frame: Up to At Least 3 Months

    Tmax of ABBV-8736.

  4. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736

    Time frame: Up to At Least 3 Months

    AUClast of ABBV-8736.

  5. AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736

    Time frame: Up to At Least 3 Months

    AUCinf of ABBV-8736.

  6. Terminal Phase Elimination Rate Constant (β) of ABBV-8736

    Time frame: Up to At Least 3 Months

    β of ABBV-8736.

  7. Terminal Elimination Half-Life (t1/2) of ABBV-8736

    Time frame: Up to At Least 3 Months

    t1/2 of ABBV-8736.

  8. Apparent Clearance of the Analyte in Serum (CL) of ABBV-8736

    Time frame: Up to At Least 3 Months

    CL of ABBV-8736.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

A Phase 1 Pharmacokinetic Study in Healthy Adult Volunteers to Evaluate the Bioavailability of ABBV-8736 Following Subcutaneous Administration Relative to Intravenous Administration

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 17, 2026
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.